Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with BMRN as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.8%||PowerShares Dynamic Biotech &Genome (PBE)||+3.82 (9.60%)|
|4.41%||VanEck Vectors Biotech ETF (BBH)||+11.88 (11.07%)|
|3.18%||PowerShares DWA Healthcare Momentum Portfolio (PTH)||+9.64 (21.59%)|
|2.22%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+13.83 (25.15%)|
|1.13%||iShares Morningstar Mid-Cap Growth ETF (JKH)||+8.12 (5.24%)|
Company Description (as filed with the SEC)
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Our product portfolio consists of five approved products and multiple clinical and pre-clinical product candidates. Our approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States (the U.S.) in February 2014, in the European Union (the EU) in April 2014 and subsequently in other countries. Naglazyme received marketing approval in the U.S. in May 2005, in the EU in January 2006 and subsequently in other countries. ... More ...
Where does BMRN fit in the risk graph?
|Annual EPS Est:||$-1.58|
|Quarterly EPS Est:||-0.4|